Malaysia-based AseaCyte is emerging as an instrumental firm in the domain of human disease analysis, through its cell culture technology and cell-based analysis services. The start-up company abides by the theories, postulated by German biologist, Dr Rudolph Carl Virchow, during the mid-19th century.

Dr Virchow, who is referred to as the 'father of modern pathology', is known for his wide contribution in the domain of cell theory. He had mentioned that diseases are caused due to the outbreak of a disturbance at the cellular level. He said that in order to understand the mystery of disease eruption and to find its solution, it is important that we know the cellular pattern and understand their behaviour.

The company has developed expertise in working with human primary cells, which are prepared from human tissues that have been sourced with ethical permission. The firm has also stringently complies with international regulations on the use of human tissues in preclinical R&D.

At Aseacyte, human and animal cells are isolated as cyro preserved stock and cell populations are characterized with cell marker analysis. Stem cells are grown in culture dishes to mimic what is happening in a whole-body environment, and can used to test a whole range of materials in a predictive way, including the complex mixture of natural compounds that is often found in herbal preparations.

AseaCyte has a bank-of-cells categorized in to diseased and healthy models. The diseased model catalogues are supportive in studying different diseases. For instance, cells from fully-characterized primary cancer cells, each isolated from individual donors and supplied with a full patient history are stored and supplied. Similarly, cells are classified for studying glioblastoma, colon cancer, lung cancer, respiratory diseases, chronic obstructive pulmonary diseases (COPD) and metabolic diseases.